2022年10月31日

看看| Clinipace宣布公司名称更改Caidya搜索工作看看| Clinipace宣布公司名称更改Caidya上海和MORRISVILLE,北卡罗来纳州,看看| Clinipace,建立临床研究机构服务全球创新者,如生物技术公司,今天宣布,它正在改变公司名称Caidya (KAY-dee-uh)。名称的改变反映了成功集成遗留品牌并购后的2021年4月。美国作为一个品牌,Caidya反映了公司的承诺帮助给国际社会带来改变人生的疗法。汇集了几十年的专家,全球影响力,和知识,Caidya给市场提供了一个独特的命题与明确专注于交付卓越帮助组织激活他们科学的全部潜力。结合公司的个性化开发方法,Caidya为创新者提供一个令人信服的选择寻找一个提升客户体验。Caidya广泛的全球业务遍及亚太、欧洲、拉丁美洲和北美洲。提供定制和可伸缩的交付模式,Caidya支持其客户在他们的整个临床过程,从pre-IND策略,通过临床开发提交和上市后监测。“Caidya的发射标志着一个令人兴奋的新一章的开始为我们的组织,我们已经捕获的本质我们带给客户在当地和全球范围内。我们现在可以继续我们的使命解放临床研究通过倾听,想公开,把每个项目的所有权和分享我们的知识在漫漫长路的每一步,”博士说Caidya董事长兼首席执行官,零十棕褐色。“我们与我们的客户合作,利用我们的专业知识和达到确保资产实现其全部的潜力我们消除障碍,有助于更好的医疗成果对于世界各地的病人,“谭博士继续说。“我们认为有一个更好的方法来做临床研究,和我们在一个路径更容易发展。” With extensive expertise in multiple therapeutic areas, such as oncology, rare diseases, neurology, infectious diseases, respiratory, and many others, Caidya understands the challenges in clinical development. Caidya helps customers pre-empt and navigate any issues using industry-leading and proprietary clinical technology to ensure trial transparency and data-driven decision-making.For more information, please visit www.caidya.com ENDS About Caidya: Caidya is a multi-therapeutic clinical research organization (CRO) serving innovators worldwide. Focused on delivery excellence and an elevated customer experience, Caidya offers a wide range of clinical services and vast therapeutic expertise, supporting its partners from pre-IND strategy, through clinical development to submission and post-marketing surveillance. Caidya leverages industry-leading and proprietary clinical technology to ensure trial transparency and data-driven decision-making. Formed in 2021 following the combination of leading CROs, dMed and Clinipace, Caidya has nearly 1,800 employees in more than 30 countries throughout the world. The Caidya group of companies includes Clinipace, Inc. Clinipace, Inc. is owned, operated, managed, and controlled by dMedClinical Co. Ltd., a privately held company, whose investors include entities located in the People’s Republic of China (PRC), and which may be subject to PRC laws and regulations that differ from those of the United States. dMedClinical’s investor group are part of a best-in-class shareholder group which includes leading global venture capital and healthcare specialists. Media contact: